Micron develops pharmaceutical products, based on its proprietary microneedle patch technology, that are designed to provide enhanced vaccines and proprietary drugs efficacy, superior patient compliance, and simplified administration, distribution, and storage logistics.

The benefits of Micron’s microneedle patch technology stem from its proprietary design and manufacturing which allow for:

  • Skin-based targeting and delivery of actives

  • Painless administration and elimination of needle phobia

  • Customizable delivery profile based on indication

  • Ease of use (no applicator required) allowing administration by minimally-trained personnel or self-administration

  • Thermostability allowing reduction or elimination of the cold chain for transportation and storage

  • Simplified logistics (transportation and storage) due to the small size and thermostability of the microneedle patch

  • No sharps waste

Micron develops pharmaceutical products, based on its microneedle patch technology, that are designed to provide enhanced protective (vaccine) and therapeutic (drugs) effects, superior patient compliance, and simplified administration, distribution, and storage logistics.

News

Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors

ATLANTA, Aug. 9, 2023 /PRNewswire/ — Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport and storage of drugs and vaccines, today announced the appointment of drug delivery and healthcare innovation veteran, Brian Bernick, MD, as Chairman of the company’s Board of Directors. “Dr. Brian Bernick has a long-standing record of…

Micron Biomedical Announces Positive Measles and Rubella Vaccination Results from First Clinical Trial of Microarray Injection-Free Vaccine Delivery in Children

Successful Phase 1/2 study is the first clinical trial of any microarray technology in pediatric populations as the need for a pain-free, logistically simplified vaccine delivery option grows worldwide. ATLANTA, May 17, 2023 /PRNewswire/ — Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport, and storage…

Micron Biomedical Extends Series A to $17 Million to Bring Needle-Free Drugs and Vaccines to Market

$3 Million Series A Extension Continues Validation of Company’s Commercial Strategy. ATLANTA, May 10, 2023 /PRNewswire/ — Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that are simplifying and advancing the delivery and administration of drugs and vaccines, today announced it has secured an additional $3 million investment from J2 Ventures, bringing…